Kodiak Sciences (KOD)

• Market cap: $171M
• 1 day: 2.18%
• 5 days: 26.43%
• 1 month: 44.67%
• 3 months: -40.03%
• 6 months: 12.87%
• Year to date: -51.16%
• 1 year: 24.93%
• 5 years: -91.89%
• 10 years: -58.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Employees: 109

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

307% more capital invested

Capital invested by funds: $103M [Q3] → $418M (+$315M) [Q4]

101% more call options, than puts

Call options by funds: $543K | Put options by funds: $270K

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

9% more funds holding

Funds holding: 97 [Q3] → 106 (+9) [Q4]

5.07% more ownership

Funds ownership: 74.85% [Q3] → 79.92% (+5.07%) [Q4]

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 29% downside
• Avg. target: $3 29% downside
• High target: $3 29% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 23% 1-year accuracy 16 / 69 met price target

29% downside $3

Neutral Reiterated

31 Mar 2025